Travere Therapeutics Reports 55.6% Revenue Growth to $127.2 Million in Q1 2026

Travere Therapeutics, Inc. reported significant financial performance for the first quarter of 2026, with total revenue reaching $127.2 million, a 55.6% increase from $81.7 million in the same period of 2025. This growth was primarily driven by a substantial rise in net product sales, which amounted to $124.5 million, up from $75.9 million year-over-year. The increase in product sales was largely attributed to the successful commercialization of FILSPARI (sparsentan), which saw sales rise to $105.2 million from $55.9 million. However, license and collaboration revenue decreased to $2.7 million from $5.9 million, reflecting a lack of significant sales of active pharmaceutical ingredients (APIs) compared to the previous year.

In terms of profitability, Travere reported a net loss of $37.1 million for the quarter, a slight improvement from the $41.2 million loss recorded in the first quarter of 2025. The company’s operating expenses increased to $164.1 million, up from $124.4 million, driven by higher research and development costs, which rose to $57.1 million from $46.9 million, and selling, general, and administrative expenses, which increased to $80.3 million from $60.4 million. The rise in expenses was linked to expanded commercial investments to support FILSPARI's launch for both IgAN and FSGS indications.

Operationally, Travere has made notable strides in its product pipeline and market presence. The company received full FDA approval for FILSPARI for the treatment of FSGS in April 2026, marking it as the first and only FDA-approved medication for this condition. Additionally, the company has expanded its international reach through licensing agreements, including a partnership with Chugai Pharmaceutical for the commercialization of sparsentan in Japan and other Asian markets. As of March 31, 2026, Travere's employee headcount increased to support its growing operations, reflecting its commitment to enhancing its commercial organization.

Looking ahead, Travere anticipates continued growth driven by the commercialization of FILSPARI and the advancement of its clinical pipeline, including pegtibatinase for classical homocystinuria. The company expects that its available cash and marketable securities, totaling $264.7 million as of March 31, 2026, will be sufficient to fund operations for the next 12 months. However, the company acknowledges that achieving profitability will depend on the successful development and market acceptance of its products, as well as navigating competitive pressures and regulatory challenges.